EPISODE · Jun 24, 2020 · 48 MIN
MIP's Charlotte Kilpatrick talks to Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences.
from MIP podcasts · host MIP
Charlotte Kilpatrick, reporter at Managing IP, sat down with Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK, to discuss how COVID-19 is reshaping the IP landscape in the life sciences industries. The guests debated IP issues including access to medicine, open science, and the role patent and technology pooling can play to accelerate vaccine research.
Embed this episode
Ready to play
MIP's Charlotte Kilpatrick talks to Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences.
No transcript for this episode yet
Similar Episodes
No similar episodes found.